London-based Ellipses Pharma said it might conduct an initial public offering (IPO) on home soil, an announcement that could mark the end for one of the longest ever dry spells for biotech listings in Britain.
Ellipses, which is developing treatments for various types of cancer, said it has signed an agreement in principle with special purpose acquisition company (SPAC) Wolfram Resources.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Ellipses and Wolfram are targeting a deal completion by early 2027, though caveated that there is no guarantee the proposed transaction will proceed.
SPACs are already listed shell companies that acquire private companies to take them public on the stock market. This method used to be considerably more common five years ago given their higher safety, though fell out of fashion after many companies with speculative growth trajectories failed to reach valuations.
With a low enthusiasm for listings on the London Stock Exchange (LSE) this year, Ellipses has so far decided to go down the SPAC route. The biotech’s non-binding Memorandum of Understanding with Wolfram will see a reverse takeover, with the latter acquiring Ellipses’ whole share capital.
There has not been a single biotech that listed on the LSE in 2026, marking one of the quietest windows in the sector’s history in the capital. Experts have also highlighted the challenging investment climate across the wider European capital markets scene.
In stark contrast, the US IPO scene has exploded in 2026. There have been around 30 biotech and pharma listings on the New York Stock Exchange (NYSE) and the Nasdaq, marking the strongest year since the 2020/2021 boom.
Targeting a listing on home soil marks a positive step for the UK biotech sector, which has seen numerous funding and exit successes this year. This week, Isomorphic Labs raised $5bn in the largest ever biotech Series C round.
Professor Sir Chris Evans, Ellipses CEO, said: “Our company has been focused resolutely on the development of promising drug candidates and the progress made with our pipeline, including encouraging results from our clinical trials for both EP0031 and EP0062, which indicates that this is now the optimal time to move towards a public listing.
The renowned British biotech entrepreneur added: “We also see our main market listing as a shot in the arm for the UK Life Sciences sector which has a great scientific pedigree.”
